Actelion

Actelion to acquire Ceptaris

Thursday, August 1, 2013 10:00 AM

San Francisco, Calif.-based pharmaceutical company Actelion will acquire Ceptaris Therapeutics, contingent upon certain closing conditions, including FDA approval of Ceptaris' product, VALCHLOR.

More... »

Actelion selects IntraLinks to streamline clinical trial info exchange

Tuesday, September 25, 2012 03:06 PM

Actelion Pharmaceuticals, a Switzerland-based biopharmaceutical company that focuses treatments to serve unmet medical needs, has selected IntraLinks, a global technology provider of inter-enterprise content management and collaboration solutions, to streamline their documentation exchange during clinical trials.

More... »

Wellington Partners announces first closing of new life science fund

Thursday, September 20, 2012 07:31 AM

Wellington Partners, a pan-European venture capital firm, announced the successful first closing of its new Wellington Partners IV Life Science Fund, which has attracted commitments from investors of $91 million.

More... »

Actelion to cut jobs, refocus R&D

Friday, July 13, 2012 03:17 PM

Switzerland-based Actelion has launched a cost saving initiative as an integral part of its strategy for value creation outlined in early May. The initiative will cut up to 135 positions and refocusing the company’s R&D activities toward orphan and specialty indications to generate additional specialty franchises, enabling it to fully capitalize on the significant growth opportunities in its core area of expertise of pulmonary arterial hypertension (PAH).

More... »

Medivir appoints Juserius commercial executive vice president

Thursday, May 17, 2012 10:44 AM

Medivir, a Stockholm-based specialty pharmaceutical company focused on infectious diseases, has appointed Henric Juserius to head the company's commercial activities.

More... »

Actelion's macitentan meets primary endpoint in phase III PAH study

Monday, April 30, 2012 12:10 PM

Switzerland-based Actelion Pharmaceuticals' initial analysis indicates that the pivotal, long-term phase III SERAPHIN study with macitentan, a novel dual endothelin receptor antagonist, has met its primary endpoint.

More... »

Auxilium and Actelion collaborate for Xiaflex

Monday, February 27, 2012 09:53 AM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company, and Actelion Pharmaceuticals have entered into a long-term partnership for the development, supply and commercialization of Xiaflex(collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.

More... »

Actelion board nominates two

Wednesday, April 6, 2011 12:40 PM

Actelion has nominated two pharmaceutical executives, including ex-GlaxoSmithKline boss Jean-Pierre Garnier, to join the board after shareholder Elliott Advisors repeated calls for changes in management and strategy, according to Pharma Times.

More... »

Actelion gets backing from shareholder

Tuesday, March 8, 2011 02:07 PM

Swiss biotech group Actelion won the support of one of its biggest shareholders after Elliott Advisers called on Actelion to consider putting itself up for sale, according to FierceBiotech.

More... »